세계의 장기칩 시장 : 제공, 유형, 제품, 재료, 용도, 최종 사용자별 예측(2025-2030년)

The Organs-on-chips Market was valued at USD 119.50 million in 2023, expected to reach USD 157.36 million in 2024, and is projected to grow at a CAGR of 33.92%, to USD 923.59 million by 2030.

Organs-on-chips represent a technological convergence of microfluidic engineering and cell biology, encapsulating living cells on microchips to simulate the physiological responses of human tissues or organs. Their necessity lies in potentially transforming the drug discovery process by providing more accurate human physiological data without resorting to animal testing. Applications of organs-on-chips range from drug testing and disease modeling to personalized medicine, where chips reflecting individual patient biology can lead to tailored therapeutic strategies. The end-use scope includes pharmaceutical companies, research institutes, biotechnology firms, and healthcare organizations.

The market for organs-on-chips is propelled by an increasing demand for predictive and precise drug development models, regulatory pushes toward alternative testing methods, and heightened investment in biotechnological research. Key growth factors include the shift towards reducing animal testing, technological advancements in chip fabrication, and an expanding scope in biomedical research. Emerging opportunities are found in the personalization of medicine and partnerships with pharmaceutical firms focusing on drug development and toxicology testing. Partners could leverage these promising tools for better predictive modeling and expedite drug development timelines. Nevertheless, challenges include high initial costs, technical complexity in mimicking specific human organ functions accurately, and the need for regulatory approvals to standardize testing methodologies across industries.

Innovative areas ripe for exploration include the development of multi-organ chips that replicate systemic physiological interactions, enhancing the biomimetic accuracy of existing chips, and optimizing the scalability for mass production. As for market nature, it's burgeoning, characterized by rapid technological advancements and significant competition among small innovative firms and established biotech companies. Recommendations for stakeholders looking to gain a competitive edge would include investment in collaborative research with academic institutions, focusing on improving chip integration, and addressing scalability to tap into the broader pharmaceutical and healthcare markets. These strategies can position organizations favorably to capitalize on the growing demand for this revolutionary technology.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Organs-on-chips Market

The Organs-on-chips Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing ethical concerns over animal testing promoting adoption of alternative testing methods
  • Rising demand for accurate drug screening and toxicity testing in the pharmaceutical industry
  • Expanding application of organs-on-chips in oncology research
• Market Restraints
  • Regulatory hurdles in approval and commercialization processes of organ-on-chip models
• Market Opportunities
  • Growing investment in personalized medicine and research initiatives for early detection of drug toxicity
  • Ongoing developments for customized organ-on-chip models for specific applications
• Market Challenges
  • Complexities associated with integrating organs-on-chips technology with the existing drug development and testing processes

Porter's Five Forces: A Strategic Tool for Navigating the Organs-on-chips Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Organs-on-chips Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Organs-on-chips Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Organs-on-chips Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Organs-on-chips Market

A detailed market share analysis in the Organs-on-chips Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Organs-on-chips Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Organs-on-chips Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Organs-on-chips Market

A strategic analysis of the Organs-on-chips Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Organs-on-chips Market, highlighting leading vendors and their innovative profiles. These include 4DCell, AlveoliX AG, AxoSim, Inc., Beonchip S. L., Bi/ond Solutions B.V., BICO Group AB, BiomimX S.r.l., Cherry Biotech, CN Bio Innovations Ltd, Curi Bio, Inc., Dynamic42 GmbH, Elvesys Group, Emulate, Inc. by UAMS, InSphero AG, Kirkstall Ltd., Micronit B.V., Mimetas B.V., NETRI SAS, Nortis Inc., SynVivo, Inc., The Charles Stark Draper Laboratory, Inc., TissUse GmbH, uFluidix, and Valo Health, Inc..

Market Segmentation & Coverage

This research report categorizes the Organs-on-chips Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Offering, market is studied across Products and Services. The Products is further studied across Consumables & Accessories, Instruments, and Software. The Services is further studied across Consulting and Maintenance & Support.
• Based on Type, market is studied across Multi-Organ-on-Chip and Single Organ-on-Chip.
• Based on Product, market is studied across Brain-on-a-chip, Heart-on-a-chip, Kidney-on-a-chip, Lung-on-a-chip, and Skin-on-a-chip.
• Based on Material, market is studied across Polymers and Silicon. The Polymers is further studied across Polydimethylsiloxane and Thermoplastics.
• Based on Application, market is studied across Drug Discovery, Physiological Model Development, and Toxicology Research.
• Based on End-user, market is studied across Academic & Research Institutes, Cosmetics Industry, and Pharmaceutical & Biotechnology Companies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing ethical concerns over animal testing promoting adoption of alternative testing methods

• 5.1.1.2. Rising demand for accurate drug screening and toxicity testing in the pharmaceutical industry

• 5.1.1.3. Expanding application of organs-on-chips in oncology research

• 5.1.2. Restraints
  • 5.1.2.1. Regulatory hurdles in approval and commercialization processes of organ-on-chip models

• 5.1.3. Opportunities
  • 5.1.3.1. Growing investment in personalized medicine and research initiatives for early detection of drug toxicity

• 5.1.3.2. Ongoing developments for customized organ-on-chip models for specific applications

• 5.1.4. Challenges
  • 5.1.4.1. Complexities associated with integrating organs-on-chips technology with the existing drug development and testing processes

• 5.2. Market Segmentation Analysis
  • 5.2.1. Offering : Proliferating use of products in pharmaceutical industry
  • 5.2.2. End-user : Expanding application of organs-on-chips (OoCs) in academic and research institutes
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Organs-on-chips Market, by Offering

• 6.1. Introduction
• 6.2. Products
  • 6.2.1. Consumables & Accessories
  • 6.2.2. Instruments
  • 6.2.3. Software
• 6.3. Services
  • 6.3.1. Consulting
  • 6.3.2. Maintenance & Support

7. Organs-on-chips Market, by Type

• 7.1. Introduction
• 7.2. Multi-Organ-on-Chip
• 7.3. Single Organ-on-Chip

8. Organs-on-chips Market, by Product

• 8.1. Introduction
• 8.2. Brain-on-a-chip
• 8.3. Heart-on-a-chip
• 8.4. Kidney-on-a-chip
• 8.5. Lung-on-a-chip
• 8.6. Skin-on-a-chip

9. Organs-on-chips Market, by Material

• 9.1. Introduction
• 9.2. Polymers
  • 9.2.1. Polydimethylsiloxane
  • 9.2.2. Thermoplastics
• 9.3. Silicon

10. Organs-on-chips Market, by Application

• 10.1. Introduction
• 10.2. Drug Discovery
• 10.3. Physiological Model Development
• 10.4. Toxicology Research

11. Organs-on-chips Market, by End-user

• 11.1. Introduction
• 11.2. Academic & Research Institutes
• 11.3. Cosmetics Industry
• 11.4. Pharmaceutical & Biotechnology Companies

12. Americas Organs-on-chips Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Organs-on-chips Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Organs-on-chips Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2023
• 15.2. FPNV Positioning Matrix, 2023
• 15.3. Competitive Scenario Analysis
  • 15.3.1. WPI and NETRI partnership promises advancements in microphysiological systems through TEER-integrated NeoBento organs-on-chip
  • 15.3.2. ESQlabs GmbH and Sanofi collaborate to revolutionize drug development with organ-on-chip technology and digital twin platforms
  • 15.3.3. CN Bio raises USD 21 million to enhance organ-on-a-chip technology, expand market reach, and improve drug development testing reliability
  • 15.3.4. German organ-on-chip specialist Dynamic42 raises Series A financing round to expand internationally
  • 15.3.5. Over Euro 3 Million for Organ-On-Chip Development
  • 15.3.6. FDA expands organ-on-a-chip research collaboration
• 15.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. 4DCell
• 2. AlveoliX AG
• 3. AxoSim, Inc.
• 4. Beonchip S. L.
• 5. Bi/ond Solutions B.V.
• 6. BICO Group AB
• 7. BiomimX S.r.l.
• 8. Cherry Biotech
• 9. CN Bio Innovations Ltd
• 10. Curi Bio, Inc.
• 11. Dynamic42 GmbH
• 12. Elvesys Group
• 13. Emulate, Inc. by UAMS
• 14. InSphero AG
• 15. Kirkstall Ltd.
• 16. Micronit B.V.
• 17. Mimetas B.V.
• 18. NETRI SAS
• 19. Nortis Inc.
• 20. SynVivo, Inc.
• 21. The Charles Stark Draper Laboratory, Inc.
• 22. TissUse GmbH
• 23. uFluidix
• 24. Valo Health, Inc.